

SenzaGen to present at EUROTOX Congress in Slovakia

SenzaGen announces today that the company will be presenting two scientific abstracts and hold a presentation titled "21st century testing: Can one test be stand alone?" at the upcoming EUROTOX Congress in Bratislava, Slovakia.

The 53rd European Congress of the European Societies of Toxicology, EUROTOX, is to be held in Bratislava, Slovakia on September 10-13, 2017. The congress will include a multitude of symposia and workshops as well as a large exhibition area and is an important meeting point for research community and industry.

On 12 September, SenzaGen's new Chief Scientific Officer Henrik Appelgren will give an Exhibitor Hosted presentation at the congress with the full title "**21st century testing for skin sensitisation: Can one test be stand alone? Regulatory challenges and GARD applications update**" Furthermore, SenzaGen is also exhibiting at the congress (Booth 25) and is presenting two scientific posters on *the transferability of the GARDskin assay to two independent laboratories and the GARD platform for potency assessment of skin sensitizing chemicals*.

For additional information regarding Henrik Appelgren's presentation, visit:
www.eurotox2017.com/programme/exhibitors-meetings/senzagen/
or SenzaGen web site www.senzagen.com/event-calendar/

For more information:

Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

About GARD

GARD™ is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have 90% reliability. This compares with the current predominant test method, experiments on mice, which has a reliability rating of 72%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen

SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

SENZAGEN AB

MEDICON VILLAGE,
SCHELEVÄGEN 2
223 81 LUND, SWEDEN

P: +46 46 2756200
W: WWW.SENZAGEN.COM
E: INFO@SENZAGEN.COM